• Exclusive global licensing agreement with Burnet Diagnostics Initiative
• Rapid test for immediate detection of liver injury through ALT measurement
• Enables early identification of liver inflammation across a range of conditions

Atomo Diagnostics Limited (ASX:AT1) has announced signing an exclusive global licensing agreement with the Burnet Diagnostics Initiative, part of The Macfarlane Burnet Institute for Medical Research and Public Health. The agreement remains in effect until the date of expiry of the last of all of the patents forming part of the Patent Rights, projected to be December 2044. The license for Burnet's novel liver function test assay supports commercialisation of a rapid test for the immediate detection of liver injury through measurement of alanine aminotransferase (ALT), a key indicator of liver inflammation and damage. Delivered on Atomo's proven Pascal cassette at the point-of-care and in the home, the test enables early identification of liver inflammation of any cause, giving the test commercial utility across a broad range of clinical applications. The initial focus is monitoring for drug-induced liver injury (DILI) where rapid elevations in ALT require an urgent clinical response. Other priority clinical applications identified by Atomo and Burnet include routine screening and monitoring of common chronic liver conditions such as viral hepatitis (B and C), fatty liver disease and alcoholic liver disease. Under the agreement, Atomo commits to pay Burnet royalty payments as a percentage of net revenues generated by the Product, with a lower royalty rate applied to sales in low-middle income countries (LMIC's) where pricing is typically lower. Atomo confirms the agreed royalty arrangements are consistent with royalties that are standard for an agreement of this nature in the diagnostics industry.

The extensive development and clinical work undertaken to date on Pascal reduces product development risk and anticipated timelines to regulatory submissions.